William J. Dawson's Location
San Francisco Bay Area, United States, United States
William J. Dawson's Contact Details
William J. Dawson work email
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
William J. Dawson personal email
n/a
William J. Dawson phone numbers
About William J. Dawson
Seasoned board member with over 50 years cumulative experience serving on public, private, and non-profit boards. Recently retired as public company CFO after 40 years with operating companies, ranging from Fortune 20 to private start-ups and investment banking firms focused in healthcare services, medical devices and biopharmaceutical companies. Experienced in corporate financial management, capital raising, M&A, and ERP implementation. Effective, fiscally disciplined organizational leader and team player with excellent people and communications skills. Undergraduate degree in Mechanical Engineering from Stanford in 1976 and MBA from Harvard in 1980.
William J. Dawson's Current Company Details
William J. Dawson Work Experience Details
-
Member Board Of DirectorsMcgrath Rentcorp 1998 - PresentLivermore, Ca, UsBoard member since 1998, current chair of Audit Committee, member and former chair of Compensation Committee, and member of Transaction Committee. Invited to join BoD of highly successful, fast growing, and profitable business-to-business rental company 14 years after being involved in its IPO. Longest tenured board member. Drove board and management to focus on building shareholder value through organic and acquired growth during which time McGrath rebuffed unsolicited takeover bid and then successfully closed and integrated three acquisitions, upgraded ERP system, and implemented SOX-compliant controls. Active in succession planning, leading to two new CEOs (both through internal promotion) and new CFO and COO (through external searches), as well as broadening divisional management structure to better achieve long-term objectives. As Compensation chair, implemented improved short and long-term cash, equity, and performance-based compensation to better align management with shareholders. Corporate governance ranked in 99th percentile for quality by ISS.
-
Member Board Of DirectorsWellington Trust Company Oct 2001 - Jun 2024One of four independent board members for trust subsidiary of Wellington Management Company, LLP, a large, private investment advisory and fund management company with offices on four continents with substantial assets under direct and sub-advisory management. Wellington Trust manages endowment and pension funds in pools representing over 100 investment styles, from U.S. government bonds to emerging market small cap equities. Member of Audit and Nominating Committees. Invited to join BoD to provide independent perspective from outside investment management industry.
-
Member Board Of DirectorsNalu Medical, Inc. Jan 2021 - Mar 2024Recruited to join the board of directors of Nalu Medical, a commercial-stage, venture-backed company focused on the design, development, and commercialization of an innovative and minimally invasive neuromodulation platform initially focused on the treatment of chronic spinal and peripheral nerve pain. Chair of Audit Committee and member of Nominating and Governance Committee.
-
Chief Financial OfficerAdamas Pharmaceuticals, Inc. Aug 2014 - Jun 2017Emeryville, California, UsCFO and member of Executive Committee of specialty pharmaceutical company developing pharmacokinetically improved therapeutics for central nervous system disorders. Responsible for finance, accounting, treasury, investment banking relationships, financial planning and analysis, audit, insurance, facilities, and, on an interim basis, information technology, business development, and program leadership. As consultant assisted in preparation for IPO in April 2014 and joined as CFO in August 2014, leading successful efforts to raise additional equity capital through $62 million follow-on and ATM vehicles with premier investment banks and $100 million royalty-backed note deal to fund U.S. commercial launch of novel Parkinson’s drug while continuing to develop late-stage pipeline in Parkinson’s, multiple sclerosis, and epilepsy. Retired in July 2017. -
Chief Financial OfficerCatalyst Biosciences Mar 2010 - Apr 2012South San Francisco, Ca, UsChief Financial Officer of Catalyst Biosciences, a private, venture-backed, development-stage biotechnology company focused on engineering bio-superior and novel proteases. Member of four-person senior management team. Responsible for finance, accounting, treasury, business development, financial planning, audit, insurance, IR/CorpComm, contracts and facilities. Joined Catalyst to lead ongoing strategic value creation effort, establishing high-level business development relationships with Big Pharma counterparties and retaining leading investment bank as exclusive advisor. Successfully renegotiated existing licensing agreement for key hemophilia asset with Pfizer on favorable terms. Led board discussions on value creation and exit strategies and tactics, corporate financial strategy and results. For more information, please visit www.catbio.com. -
Vp, Finance & CfoCerus Corporation Aug 2004 - Apr 2009Concord, California, UsVice President, Finance and Chief Financial Officer, responsible for finance, accounting, treasury, audit, insurance, IR/CorpComm, and financial planning functions at public, commercial-stage biomedical device company. Joined Cerus in mid-2004 along with CEO to effect turnaround. Led effort to reposition company, emphasizing financial discipline, measured investment in core business, and cultivation of new buy- and sell-side relationships, while spinning off development-stage immunotherapy business to syndicate of leading venture capital firms. Launched new corporate website and developed collateral IR material reflecting repositioning. Completed successful follow-on public and registered direct equity offerings, raising $71.4 million from 30 new institutional investors. Added four new sell-side research analysts. Frequent presentations to board, institutional investors, and sell-side research analysts. Participated in successful launch of European subsidiary. Reorganized and staffed international finance/accounting teams to function more efficiently in multi-national public company context. Led efforts to strengthen governance policies, timely and accurate SEC filing processes, and procedures required by Sarbanes-Oxley Act, leading to five years with no material weaknesses and, in most recent year, no significant deficiencies. Developed long-term planning tool to forecast more accurately funding requirements of international operations and improve working capital management. Actively implemented plan through staffing cuts and policy changes to substantially reduce operating expenses and investment in working capital, while product sales rose five fold, resulting in 50% reduction in cash burn. -
Vice President, Operations And CfoDynavax Technologies Corporation Mar 2002 - Jun 2004Vice President, Finance & Operations, and Chief Financial Officer, responsible for finance, accounting, treasury, audit, IT, IR/PR, and planning functions at public, development-stage biopharmaceutical company. Led effort to finance hepatitis B program franchise, writing business plan, leading negotiations, and coordinating documentation, culminating in October 2003 formation of Dynavax Asia, a newly formed Singapore-based subsidiary, raising $15.2 million from international consortium of institutional investors at 20% premium to prior round. Generated business plan for allergy program franchise, leading to major strategic collaboration in February 2004 with European pharmaceutical company, yielding more than $100 million in potential program funding. Led successful IPO process, coordinating legal, accounting, and investment banking resources, raising $51.8 million in difficult market conditions in February 2004. Established broad relationships with Wall Street and buy-side institutional investors. Rebuilt and organized finance and accounting team to function in public company context. Galvanized relationships with external legal and accounting firms, implementing governance policies, SEC filing processes, and procedures required by Sarbanes-Oxley Act. Recruited to Dynavax to provide general business compliment to science-driven management team.
-
Corporate Senior Vice President, Business DevelopmentMckesson Corporation Sep 1998 - May 2001Irving, Texas, UsCorporate Senior Vice President, Business Development, reporting directly to CEO. Responsible for corporate-wide M&A and venture capital investment program of Fortune 30 healthcare services company. Implemented disciplined M&A planning, diligence, analysis, and processing systems and recruited professional staff. Led acquisitions of five healthcare businesses for aggregate purchase price of over $500 million and divestiture of major non-core business for $1.1 billion. Frequent presentations to board, institutional investors, and sell-side research analysts. Directed over $100 million in total venture investments, including $68 million in early stage operating companies, achieving 85% IRR and 3x cash-on-cash return during two-year investment cycle. As SVP, Corporate Development and Acting CFO of iMcKesson, LLC (wholly owned subsidiary of McKesson), member of senior management team responsible for forming, repositioning, and operating e-health business unit with $300 million in revenue and positive operating cash flow. -
Corp Svp, Business DevelopmentMckesson Corporation 1998 - 2001Irving, Texas, Us
-
Managing DirectorVolpe, Brown, Whelan 1993 - 1998Managing Director responsible for new business development, client relationships, and management of transaction processing spanning several sectors of healthcare on international basis. Directed firm’s efforts in drug discovery technologies (bioinformatics, functional genomics, and high-throughput screening) and drug delivery technologies (transdermal, pulmonary, sustained release oral, gene vectoring, etc.), building latter into internationally dominant practice area. Also directed firm’s activities in physician practice management, healthcare information, dental distribution, and disease management sectors, as well as for selected medical device clients. Member, M&A/Private Placement Commitment Committee. Responsible for recruiting, training, and mentoring all Associates and Principals within Corporate Finance Group. Initiated, conducted due diligence, and closed several venture investments made by firm and its officers.
William J. Dawson Education Details
-
Harvard Business SchoolGeneral Management -
Stanford UniversityDept. Of Architecture
Frequently Asked Questions about William J. Dawson
What company does William J. Dawson work for?
William J. Dawson works for Mcgrath Rentcorp
What is William J. Dawson's role at the current company?
William J. Dawson's current role is Experienced corporate board member.
What is William J. Dawson's email address?
William J. Dawson's email address is bi****@****tbi.com
What is William J. Dawson's direct phone number?
William J. Dawson's direct phone number is +151045*****
What schools did William J. Dawson attend?
William J. Dawson attended Harvard Business School, Stanford University.
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial